Merus NV (NASDAQ:MRUS) Receives Average Recommendation of “Buy” from Analysts

Share on StockTwits

Merus NV (NASDAQ:MRUS) has been given an average recommendation of “Buy” by the nine brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $24.00.

Several equities research analysts have weighed in on the company. Zacks Investment Research raised Merus from a “sell” rating to a “hold” rating in a research report on Friday, February 7th. ValuEngine lowered Merus from a “hold” rating to a “sell” rating in a research report on Thursday, January 16th. BidaskClub raised Merus from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, Guggenheim assumed coverage on Merus in a research report on Wednesday, November 20th. They issued a “buy” rating and a $25.00 target price on the stock.

Shares of MRUS opened at $18.61 on Friday. The business’s fifty day moving average price is $16.11 and its 200 day moving average price is $16.39. Merus has a 12-month low of $11.00 and a 12-month high of $20.95. The stock has a market capitalization of $435.61 million, a PE ratio of -14.43 and a beta of 0.10.

Merus (NASDAQ:MRUS) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.07. Merus had a negative return on equity of 40.56% and a negative net margin of 90.21%. The firm had revenue of $9.02 million for the quarter, compared to analysts’ expectations of $7.79 million. Sell-side analysts predict that Merus will post -1.71 EPS for the current year.

In other Merus news, major shareholder Bvf Partners L. P/Il purchased 278,730 shares of the stock in a transaction dated Thursday, January 16th. The shares were bought at an average cost of $16.15 per share, with a total value of $4,501,489.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Value Fund L. P. Biotechnology purchased 83,962 shares of the stock in a transaction dated Monday, January 13th. The shares were acquired at an average cost of $15.60 per share, for a total transaction of $1,309,807.20. The disclosure for this purchase can be found here.

Several institutional investors and hedge funds have recently modified their holdings of MRUS. UBS Group AG acquired a new position in shares of Merus during the fourth quarter valued at $30,000. Marshall Wace North America L.P. acquired a new position in shares of Merus during the fourth quarter valued at $34,000. Tower Research Capital LLC TRC acquired a new position in shares of Merus during the third quarter valued at $48,000. California Public Employees Retirement System increased its holdings in shares of Merus by 14.4% during the fourth quarter. California Public Employees Retirement System now owns 11,441 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 1,441 shares during the period. Finally, Acadian Asset Management LLC increased its holdings in shares of Merus by 29.5% during the fourth quarter. Acadian Asset Management LLC now owns 12,035 shares of the biotechnology company’s stock valued at $170,000 after purchasing an additional 2,740 shares during the period. 50.77% of the stock is currently owned by institutional investors.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Featured Article: Learning About the VIX – Volatility Index

Analyst Recommendations for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.